[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iron-deficiency-anemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iron-deficiency-anemia":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,50,84,111,144,170,202,231,262,293,313,335,357,380,404,435,460,486,507,532,559,584,606,632,663],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100641079","daily-versus-alternate-day-oral-iron-therapy-for-anemia-in-second-trimester-pregnancy-100641079",false,"NCT07657455","Daily Versus Alternate-Day Oral Iron Therapy for Anemia in Second-Trimester Pregnancy","Daily Versus Alternate-Day Oral Iron Therapy for Anemia Correction in Second-Trimester Pregnant Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 40 years\n* Pregnant women in the second trimester (13 to 27 weeks gestation)\n* Hemoglobin below 11 g\u002FdL with serum ferritin below 30 ng\u002FmL\n* Singleton pregnancy\n\nExclusion Criteria:\n\n* Known congenital or acquired hemoglobin disorders (e.g., thalassemia, hemoglobinopathies)\n* Chronic diseases affecting hemoglobin levels (e.g., chronic kidney disease, inflammatory disorders)\n* Bleeding disorders or a history of frequent blood loss\n* Gastrointestinal conditions impairing nutrient absorption (e.g., celiac disease or other malabsorption syndromes)\n* Currently receiving parenteral iron\n* Requiring blood transfusion","FEMALE","18 Years","40 Years",{"count":21,"type":22},184,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized controlled trial compares daily versus alternate-day oral iron supplementation in pregnant women with iron deficiency anemia during the second trimester. The study evaluates changes in hemoglobin and serum ferritin, treatment adherence, and gastrointestinal side effects to inform more patient-centered, physiologically aligned dosing strategies.",[28,29],"Iron Deficiency Anemia","Anemia in Pregnancy",[31,32,33,34,35,36],"oral iron","ferrous sulfate","alternate-day dosing","hepcidin","second trimester","adherence","NOT_YET_RECRUITING","2026-06-14",{"date":40,"type":41},"2026-06-18","ACTUAL",{"date":43,"type":22},"2026-09",{"date":45,"type":22},"2027-02",{"name":47,"class":48},"Pakistan Air Force (PAF) Hospital Islamabad","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":49},"100642434","face-apps-based-approach-for-improving-iron-deficiency-anaemia-indicators-among-female-adolescents-at-marginalized-communities-100642434","NCT07633262","FACE-APPS-Based Approach for Improving Iron Deficiency Anaemia Indicators Among Female Adolescents at Marginalized Communities","FACE-APPS-Based Approach for Improving Iron Deficiency Anaemia Indicators Among Female Adolescents at Marginalized Communities: A Randomized Control Trial","Inclusion Criteria:\n\n* Adolescent females aged 14-17 years\n* who are attending high school\n* who have haemoglobin levels \\\u003C12 mg\u002Fdl and serum ferritin levels below 15 μg\u002FL\n\nExclusion Criteria:\n\n* Adolescents have other causes of anemia, such as thalassemia and sickle cell anemia, and malaria will be excluded.\n* Adolescents with chronic diseases that affect iron metabolism (e.g., chronic kidney disease) or other severe illnesses or conditions that may interfere with active participation.\n* Pregnant females will be excluded (if included in the age group).\n* Adolescents with gastrointestinal ulcers, colon polyps, or cancers; celiac disease; Crohn's disease; or gastric bypass surgery.",true,"14 Years",{"count":60,"type":22},160,[25],"This study aims to evaluate the effect of the Face-to-face Assisted Counselling with Enhanced Application School-Based Approach (FACE-APPS-Based Approach) on anemia indicators among female adolescents.\n\nThe study is a prospective, randomized controlled trial. A total of 160 female adolescents with hemoglobin levels below 12.0 g\u002FdL will be recruited from 7 secondary schools. Random assignment at the individual level, stratified by baseline anemia status, will be used to ensure balance. For participants in the intervention group, the intervention will be designed by an interdisciplinary team and administered over 4 months, comprising 8 face-to-face counseling sessions and 8 parallel mobile application modules. Control group participants will receive standard care (diagnosis and referral). The primary outcomes are the mean differences in hemoglobin and serum ferritin levels. Secondary outcomes are engagement among female adolescents (attendance at counseling sessions and completion of mobile application modules).",[28,64,65],"Digital Health Literacy","Health Promotion Model (HPM)",[67,68,69,70,71,72,73],"blended intervention","health promotion","iron deficiency anemia","adolescent females","adolescent behavior","female adolescents","marginalized communities","RECRUITING","2026-06-08",{"date":77,"type":41},"2026-06-10",{"date":79,"type":41},"2026-05-24",{"date":81,"type":22},"2026-11-30",{"name":83,"class":48},"Cairo University",{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":92,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":49},"100517070","the-effect-of-combined-iron-protocols-on-perioperative-allogeneic-transfusion-100517070","NCT06012760","The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion","Effect of Iron Sucrose Combined With Human Erythropoietin and Vitamin C on Perioperative Allogeneic Red Blood Cell Infusion in Major Cardiac Surgery","CIPAT","Inclusion Criteria:\n\n1. Participants must be at least 18 years of age.\n2. Major cardiac surgery should encompass procedures such as coronary artery bypass grafting (CABG), valve surgery, or a combination of both.\n3. Iron deficiency anemia is defined as having a ferritin level below 100 μg\u002FL or a ferritin level below 300 μg\u002FL accompanied by a transferrin saturation below 25%. Additionally, hemoglobin levels should range between 90 and 130 g\u002FL for men or between 90 and 120 g\u002FL for women.\n4. The American Society of Anesthesiologists (ASA) classification should fall within Grade 1-3.\n5. Prior to participation, the patient or their legal representative must provide informed consent.\n\nExclusion Criteria:\n\n1. Contraindications for the administration of iron sucrose, ascorbic acid, or rHuEPO.\n2. Presence of a temperature exceeding 37.5 °C or the utilization of non-prophylactic antibiotics.\n3. Individuals with a weight equal to or less than 50kg.\n4. Individuals with a family history of haemochromatosis or thalassaemia, or those with a transferrin saturation level exceeding 50% or a documented history of iron overload.\n5. Presence of other known haematological disorders such as folic acid or vitamin B12 deficiency, haemolytic anaemia, haemoglobinopathies, iron granulocytic anaemia, G6PD deficiency, etc.\n6. Requirement for emergency surgical intervention.\n7. Severe hepatic or renal impairment, ALT \\>3 times the upper limit of normal value or AST \\>3 times the upper limit of normal value, creatinine \\>1.5 times the upper limit of normal value\n8. Pregnant or lactating women\n9. history of blood transfusion, intravenous iron or ascorbic acid use within 12 weeks prior to surgery\n10. Acute blood loss, gastrointestinal bleeding, etc. in the preoperative period.","ALL",{"count":94,"type":22},400,[25],"The goal of this clinical trial is to learn if a combined iron supplementation regimen can reduce the need for blood transfusions in adults with iron-deficiency anemia undergoing major elective cardiac surgery. The trial will also look at whether this regimen is safe and well tolerated. The main questions it aims to answer are:\n\nDoes the combined regimen lower the amount of allogeneic red blood cell transfusion needed during and after surgery?\n\nAre there any side effects or safety concerns associated with the regimen?\n\nResearchers will compare the combined iron supplementation (sucrose iron, erythropoietin, and vitamin C) to standard care to see if it helps reduce blood transfusions.\n\nParticipants will:\n\nReceive either the combined regimen or standard care before surgery\n\nUndergo major elective cardiac surgery under general anesthesia\n\nBe monitored for blood transfusion needs and recovery up to 90 days after surgery",[98,28,99,100,101],"Anemia","Perioperative","Transfusion","Cardiac Surgery","2026-05-29",{"date":104,"type":41},"2026-06-02",{"date":106,"type":41},"2025-01-04",{"date":108,"type":22},"2028-03-31",{"name":110,"class":48},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":92,"minAge":4,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":49},"100465418","phase-2-darbe-plus-iv-iron-to-decrease-transfusions-while-maintaining-iron-sufficiency-in-preterm-infants-100465418","NCT05340465","Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants","Trial of Darbepoetin Plus Slow-release Intravenous Iron to Decrease Transfusions and Improve Iron Status and Neurodevelopment in Preterm Infants","DIVI","Inclusion Criteria:\n\n• NICU patients (male and female) born at 24-0\u002F7 to 31-6\u002F7 weeks of gestation\n\nAll patients who meet inclusion criteria will be approached without regard to sex, race, ethnicity, parents' country of origin, or religious preferences.\n\nExclusion Criteria:\n\n* Known fetal\u002Finfant anomalies of clinical significance (brain, cardiac, chromosomal anomalies)\n* Parental consent unable to be obtained by 72 hours after birth\n* Central hematocrit \\> 65%\n* Evidence of high iron stores prior to enrollment (e.g. Ferritin \\>400 ng\u002FmL with corresponding ZnPP\u002FH of \\\u003C30, Transferrin saturation \\>75%, iron \\> 200 mcg\u002FdL, TIBC \\\u003C 100 mcg\u002FdL)\n* Culture proven sepsis, meningitis, urinary tract infection, or other significant infection at the time of enrollment\n* Mother under 18 years of age\n* Unable to consent in English or Spanish","3 Days",{"count":121,"type":22},120,[123],"PHASE2","In this phase II trial, the investigators overarching goal is to demonstrate the feasibility and potential benefit of darbepoetin (Darbe) plus slow-release intravenous (IV) iron to decrease transfusions, maintain iron sufficiency and improve the neurodevelopmental outcomes of preterm infants.\n\nInvestigators hypothesize that in infants \\\u003C 32 completed weeks of gestation, combined treatment with Darbe plus Ferumoxytol (FMX) or Darbe plus low molecular weight iron dextran (LMW-ID) will: 1) be safe, 2) decrease or eliminate transfusions, 3) maintain iron sufficiency, 4) result in higher hematocrit and 5) improve neurodevelopment. Investigators further hypothesize that when compared to oral iron supplementation (standard care), IV iron will be better tolerated, with less effect on the gastrointestinal (GI) microbiome",[126,127,28,128],"Prematurity","Iron-deficiency","Iron Malabsorption",[130,131,132,133,134],"prematurity","iron deficiency","anemia","darbepoetin","IV Iron","2026-05-21",{"date":137,"type":41},"2026-05-26",{"date":139,"type":41},"2022-11-27",{"date":141,"type":22},"2027-06-30",{"name":143,"class":48},"University of Washington",{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":17,"minAge":151,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":155,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":49},"100640029","phase-4-acupoint-tens-vs-resistance-training-for-iron-deficiency-anemia-100640029","NCT07605676","Acupoint TENS vs Resistance Training for Iron Deficiency Anemia","Effect of Transcutaneous Electrical Acupoint Stimulation Versus Resistance Exercise on Hemoglobin Level in Women With Iron Deficiency Anemia","Inclusion Criteria:\n\n* Sixty women diagnosed with iron deficiency anemia within ≤6 months.\n* Their hemoglobin concentrations ranging from 8.0 to 10.9 g\u002FdL that classified as moderate anemia in accordance with the World Health Organization (WHO) criteria.\n* The iron deficiency anemia resulted from the heavy monthly bleeding of menstrual cycle as reported by the women.\n* Their age will be ranged from 20 and 30 years old.\n* Their BMI will be ranged from 18.5 to 24.9 kg\u002Fm².\n* They will have the same level of functional capacity assessed by 6-minute walking test.\n* They will be receiving the same medical treatment programme.\n\nExclusion Criteria:\n\n* Other causes of anemia (e.g., hemolytic anemia, anemia of chronic disease, megaloblastic anemia, thalassemia, or sickle cell disease).\n* Severe anemia (hemoglobin \\\u003C 8.0 g\u002FdL)\n* History of chronic kidney disease, liver disease, or malignancy.\n* Current pregnancy or lactation, due to altered iron metabolism and hemoglobin thresholds.\n* Recent blood transfusion or iron therapy (oral or intravenous) within the past 3 months.\n* Use of hematopoietic agents (e.g., erythropoietin).\n* Acute infection or inflammatory conditions at the time of enrollment.\n* Inability or unwillingness to provide informed consent or comply with study procedures.\n* Previous participation in complementary treatments\u002Fresearch within the last six months.","20 Years","30 Years",{"count":154,"type":22},60,[156],"PHASE4","The current study is designed to compare between the effect of transcutaneous electrical acupoint stimulation and resistance exercises on hemoglobin level in women with iron deficiency anemia.The design of this study will be a randomized controlled trial (RCT) pretest post-test assessment.Sixty women diagnosed with iron deficiency anemia will be recruited in this study from Kafrelshiekh University Hospital, Kafrelshiekh Governorate, Egypt. Their ages will be ranged from 20 to 30 years old, and they will be randomly divided into three equal (n= 20) groups. Change in hemoglobin concentration (g\u002FdL) after the intervention period and changes in RBC count, MCV, MCH, RDW, serum ferritin, fatigue level, and functional exercise capacity after treatment will be measured.",[28],[160,161,162,28],"Acupoint TENS","Resistance Exercise","Hemoglobin levels","2026-05-18",{"date":137,"type":41},{"date":166,"type":41},"2026-01-15",{"date":168,"type":22},"2026-10-15",{"name":83,"class":48},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":92,"minAge":178,"maxAge":18,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":188,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":49},"100600265","pediatric-outcomes-and-recovery-with-peri-operative-iron-supplement-evaluation-100600265","NCT07095244","Pediatric Outcomes and Recovery With Peri-Operative Iron Supplement Evaluation","Pediatric Outcomes and Recovery With Peri-Operative Iron Supplement Evaluation (PORPOISE)","PORPOISE","Inclusion Criteria:\n\n* All patients scheduled for VDRO and\u002For pelvic osteotomy surgery (prospective cohort)\n* All patients who had VDRO and\u002For pelvic osteotomy surgery between February 2022 and December 2024 (historical cohort)\n* Ages 0-18 years old\n\nNote that the investigators will include patients who do or do not have a diagnosis of a neuromotor condition. The investigators may not include patients who are enrolled in other conflicting research studies.\n\nExclusion Criteria:\n\n* Patients who have undergone a major surgical intervention in the last 3 months\n* Patients who have received a nutritional intervention that includes iron testing and treatment within the last 3 months\n* Patients in whom oral\u002Fenteral iron supplementation is contraindicated\n* Patients who have a bleeding disorder\n* Patients taking erythropoietin\n* Patients who cannot read and understand English\\*\n\n  * Patients and their families who cannot read and understand English will be excluded from the study because the surveys and interviews are conducted in English. These patients will still have access to the same nutrition management and interventions as study participants.","0 Years",{"count":180,"type":22},180,[25],"Varus-derotation osteotomy (VDRO) is a surgery to prevent or address hip displacement in children. Many children having this surgery have cerebral palsy or other neuromotor disorders, who have a higher rate of malnutrition, including low iron or anemia. This can affect their surgical outcomes, such as increasing their need for blood transfusions. This project aims to develop a preoperative nutritional program for VDRO patients, to improve their surgical outcomes and decrease their need for transfusions. This may include taking iron supplementation for patient with low iron or anemia. Participants will undergo a nutrition program before their surgery.",[184,185,186,187],"Varus-Derotation Osteotomy Surgery","Iron-deficiency Anemia","Pelvic Osteotomy Surgery","Cerebral Palsy",[189,98,190,191,192],"Varus-derotation osteotomy","Iron deficiency","Nutrition","Perioperative blood management","2026-05-11",{"date":195,"type":41},"2026-05-14",{"date":197,"type":41},"2025-09-01",{"date":199,"type":22},"2027-12-31",{"name":201,"class":48},"University of British Columbia",{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":92,"minAge":210,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":213,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":230},"100432633","phase-4-intravenous-iron-to-treat-postoperative-anemia-in-older-cardiac-surgery-patients-100432633","NCT04913649","Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients","Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients: a Randomized Controlled Trial'","AGE-ANEMIA","Inclusion Criteria:\n\n* Mentally competent with age ≥ 70 years\n* Elective AVR or CABG surgery\n* Expected uncomplicated postoperative trajectory, defined as:\n* No inotropic agents or ventilation at time of final inclusion (POD 1)\n* Expected discharge to general ward at POD 1\n* Moderate postoperative IDA, defined as:\n* Hb between 85 and 110 g\u002FL and\n* Ferritin \\\u003C100 µg\u002FL or\n* Iron saturation (TSAT) \\\u003C 20%\n\nExclusion Criteria:\n\n* Medical history of iron overload\u002Fhaemochromatosis\n* Medical history of liver cirrhosis or ALT\u002FAST value in blood serum triple of normal value (female patients: ALT \\>120, AST \\>105 U\u002FL. Male patients: ALT\\>150, AST\\>135 U\u002FL)\n* Severe renal failure (eGFR\\\u003C15ml\u002Fmin\u002F1.73m2)\n* Recent treatment with IVI (\\\u003C12 weeks prior)\n* Serious or severe allergic reaction to IVI in medical history\n* Severe asthma or eczema in medical history (atopic constitution)","70 Years",{"count":212,"type":22},310,[156],"Postoperative anemia is common in cardiac surgery with cardiopulmonary bypass. Iron deficiency delays the recovery from postoperative anemia and may negatively affect the postoperative trajectory of cardiac surgery patients. The objective of the study is to determine the effect of treatment of postoperative iron deficiency anemia with intravenous iron on disability 90 days after surgery. This will be evaluated in a randomized placebo-controlled double blind two-center trial in which 310 elective cardiac surgery patients will be included.",[28],[217,218,219,220],"Cardiac surgery","Postoperative anemia","Intravenous iron","Postoperative disability","2026-04-22",{"date":223,"type":41},"2026-04-27",{"date":225,"type":41},"2021-09-23",{"date":227,"type":22},"2026-12",{"name":229,"class":48},"dr. P. Noordzij",2,{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":92,"minAge":238,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":261},"100354295","phase-3-a-study-to-evaluate-ferumoxytol-for-the-treatment-of-iron-deficiency-anemia-ida-in-pediatric-subjects-100354295","NCT03893045","A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects","A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects","Inclusion Criteria:\n\n1. Male or female 2 years to \\\u003C18 years of age at time of consent\n2. Has IDA defined as:\n\n   1. Hemoglobin (Hgb) \\\u003C11.0 g\u002FdL AND\n   2. Any one or more of the following:\n\n      * Transferrin saturation (TSAT) \\\u003C20%\n      * ferritin \\\u003C100 ng\u002FmL\n3. Documented history of unsatisfactory oral iron therapy or in whom oral iron cannot be tolerated, or for whom oral iron is considered medically inappropriate\n\nExclusion Criteria:\n\n1. Known hypersensitivity reaction to any component of ferumoxytol or iron sucrose\n2. History of allergy to intravenous (IV) iron\n3. History of ≥2 clinically significant drug allergies\n4. Subjects with CKD (defined as eGFR of \\\u003C60 mL\u002Fmin\u002F1.73 m2 or a requirement for chronic hemodialysis or peritoneal dialysis during Screening)\n5. Low systolic blood pressure (BP) (age 1 to 9 years \\\u003C70 + \\[age in years x 2\\] mmHg, age 10 to 17 years \\\u003C90 mmHg)\n6. Hgb ≤7.0 g\u002FdL\n7. Serum ferritin level \\>600 ng\u002FmL","2 Years","17 Years",{"count":241,"type":22},75,[243],"PHASE3","This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric subjects (2 years to \\\u003C18 years of age) with IDA, or felt by their clinician to be at risk of developing IDA. This study allows for enrollment of subjects with IDA regardless of etiology, except for CKD subjects (pediatric CKD subjects are being studied in a separate ferumoxytol protocol).",[28],[247,132,248,249,250],"IDA","pediatrics","ferumoxytol","iron sucrose","2026-04-14",{"date":253,"type":41},"2026-04-17",{"date":255,"type":41},"2019-09-18",{"date":257,"type":22},"2026-10",{"name":259,"class":260},"AMAG Pharmaceuticals, Inc.","INDUSTRY",15,{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":92,"minAge":18,"maxAge":269,"enrollmentInfo":270,"targetDuration":272,"studyType":273,"phases":4,"briefSummary":274,"conditions":275,"keywords":278,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":49},"100623510","iron-supplementation-and-anemia-after-sleeve-gastrectomy-100623510","NCT07397572","Iron Supplementation and Anemia After Sleeve Gastrectomy","Prophylactic Oral Iron Supplementation for the Prevention of Iron Deficiency Anemia After Sleeve Gastrectomy: A Prospective Comparative Cohort Study","Inclusion Criteria:\n\n* Adults aged 18 to 65 years scheduled to undergo primary laparoscopic sleeve gastrectomy (LSG).\n* Capable of understanding and providing written informed consent for participation.\n* Able and willing to commit to the 6-month post-operative follow-up schedule at the bariatric clinic.\n\nExclusion Criteria:\n\n* Prior history of major gastrointestinal surgery (e.g., bowel resection, gastrectomy) that could independently affect iron absorption.\n* Pre-existing malabsorptive conditions (e.g., inflammatory bowel disease, celiac disease).\n* Diagnosis of other known forms of anemia (e.g., thalassemia, vitamin B12\u002Ffolate deficiency, anemia of chronic disease) that would confound the diagnosis of iron deficiency anemia (IDA).\n* Any condition that, in the investigator's judgment, would interfere with full participation in the study or pose a significant risk.","65 Years",{"count":271,"type":22},66,"6 Months","OBSERVATIONAL","The goal of this observational study is to learn if taking extra iron pills after weight loss surgery helps prevent low iron and anemia compared to just taking a standard multivitamin. The main question it aims to answer is:\n\nDoes a specific iron supplementation plan lower the number of patients who develop iron deficiency anemia in the 6 months after sleeve gastrectomy surgery?\n\nResearchers will compare two groups of patients from different hospital units to see if the extra iron works:\n\nPatients from one unit who take a prophylactic iron supplement (Ferrodep, 60 mg per day) in addition to their standard multivitamin.\n\nPatients from another unit who take only a standard multivitamin (Centrum Silver).\n\nParticipants in this study will:\n\n* Have their blood tested for iron and anemia levels before surgery, and again at 3 and 6 months after surgery, as part of their regular post-operative care.\n* Be asked about their health and quality of life during follow-up clinic visits.\n* Have their medical information from their hospital records reviewed by the study team to track their progress.",[28,276,277],"Obesity","Sleeve Gastrectomy",[279,280,28,281,282,283,284],"Laparoscopic Sleeve Gastrectomy","Bariatric Surgery","Iron Supplementation","Multivitamin","Morbid Obesity","Observational Study","2026-02-07",{"date":287,"type":41},"2026-02-11",{"date":289,"type":41},"2026-01-17",{"date":291,"type":22},"2027-01",{"name":83,"class":48},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":57,"sex":92,"minAge":272,"maxAge":299,"enrollmentInfo":300,"targetDuration":4,"studyType":23,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":230},"100623033","phase-4-alternate-day-versus-daily-oral-iron-therapy-in-children-with-iron-deficiency-anaemia-100623033","NCT07391371","Alternate-day Versus Daily Oral Iron Therapy in Children With Iron Deficiency Anaemia","Inclusion criteria Six months to 12 years old children with iron deficiency anaemia\n\nExclusion criteria\n\n1. Critically ill child\n2. Children with documented chronic illnesses (e.g., known renal failure, known liver disease)\n3. Children with known cases of thalassemia\n4. Children with severe anaemia requiring transfusion\n5. Children who received blood transfusion within the preceding 3 months","12 Years",{"count":154,"type":22},[156],"The goal of this clinical trial is to find out whether Iron (III)-hydroxide polymaltose complex (IPC) given on an alternate-day schedule works as well as daily dosing in treating iron deficiency anaemia in children. The study will also look at the safety and tolerability of IPC.\n\nThe main questions this study aims to answer are:\n\nDoes alternate-day oral IPC improve haemoglobin levels and serum ferritin level as effectively as daily oral IPC?\n\nDoes alternate-day dosing reduce gastrointestinal side effects compared to daily dosing?\n\nDoes alternate-day dosing improve treatment adherence in children?\n\nResearchers will compare alternate-day IPC with daily IPC to determine the most effective and well-tolerated dosing schedule for children with iron deficiency anaemia.\n\nParticipants will:\n\nReceive oral Iron (III)-hydroxide polymaltose complex either daily or on alternate days for 12 weeks treatment period\n\nAttend regular clinic visits for clinical assessment and blood investigations\n\nBe monitored for adverse effects, adherence to treatment, and improvement in haemoglobin and serum ferritin levels",[28],"2026-01-29",{"date":306,"type":41},"2026-02-05",{"date":308,"type":22},"2026-02-01",{"date":310,"type":22},"2027-01-31",{"name":312,"class":48},"University of Medicine, Mandalay",{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":92,"minAge":320,"maxAge":18,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":4},"100558380","phase-4-daily-iron-vs-every-other-day-iron-for-pediatric-patients-with-ida-100558380","NCT06550362","Daily Iron vs Every-other-day Iron for Pediatric Patients With IDA","A Randomized Controlled Trial Comparing Daily Oral Iron Administration to Every Alternate Day Iron Administration in the Treatment of Iron Deficiency Anemia in Pediatric Patients.","Inclusion Criteria:\n\n* Confirmed Iron Deficiency Anemia\n* Pediatric patients (1-18 years of age) without regard of gender, race, ethnicity nor language.\n* Able and willing to take oral iron (tablet or liquid).\n\nExclusion Criteria:\n\n* Pregnant or lactating patients\n* Known allergies or intolerance to oral iron formulations\n* Concomitant chronic medical conditions affecting iron metabolism\n* Short gut syndrome\n* Celiac disease\n* Inflammatory bowel disease\n* Cancer\n* Chronic kidney disease\n* Blood transfusions in the past 3 months\n* IV iron administration in the past 3 months\n* Oral iron supplementation in the past 2 weeks","1 Year",{"count":322,"type":22},100,[156],"Iron Deficiency Anemia (IDA) is a prevalent global health issue affecting a significant proportion of the population, including children. While daily oral iron supplementation is a common approach to treat IDA, concerns regarding side effects and compliance have led to exploration of alternative dosing schedules, such as every-other-day. This study aims to investigate the efficacy and safety of daily versus every other day oral iron supplementation in the management of IDA in pediatric patients.",[28],"2026-01-28",{"date":328,"type":41},"2026-01-30",{"date":330,"type":22},"2026-05",{"date":332,"type":22},"2027-05",{"name":334,"class":48},"Loma Linda University",{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":92,"minAge":18,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":344,"briefSummary":345,"conditions":346,"keywords":347,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":355,"locationsCount":49},"100615036","phase-4-sucrosomial-vs-intravenous-iron-for-preoperative-anemia-100615036","NCT07287371","Sucrosomial Vs Intravenous Iron for Preoperative Anemia","Randomized Trial of Sucrosomial Iron Vs Intravenous Iron for Preoperative Anemia (RSIVI)","RSIVI","Inclusion Criteria:\n\n* Age ≥18 years\n* Scheduled for elective cardiac surgical procedures, including:\n* Coronary artery bypass graft surgery (CABG)\n* Valve procedures\n* Aortic root procedures\n* Transcatheter aortic valve implantation (TAVI)\n* Hemoglobin \\\u003C12 g\u002FdL and ≥10 g\u002FdL on a complete blood count obtained at the Center for Perioperative Medicine pre operative visit\n* Evidence of iron deficiency\n* Able to provide informed consent\n* Able to understand spoken and written English\n\nExclusion Criteria:\n\n* Scheduled for cardiac surgery requiring deep hypothermia or circulatory arrest\n* Undergoing heart transplantation or ventricular assist device placement\n* Lacking capacity to provide informed consent or unable to understand spoken and written English\n* Baseline hemoglobin \\>12 g\u002FdL or \\\u003C10 g\u002FdL\n* Use of anticoagulant medications within 5 days of the Center for Perioperative Medicine visit, or planned initiation of anticoagulant therapy before surgery\n* History of hemoglobinopathy\n* History of hematologic malignancy\n* Bone marrow suppression from non nutritional causes\n* Vitamin B12 or folate deficiency\n* Known liver disease\n* Known kidney disease\n* Normal serum iron studies at baseline",{"count":241,"type":22},[156],"50 patients with anemia scheduled for heart surgery or procedures will be randomized to receive either oral sucrosomial iron or standard-of-care intravenous iron before surgery to see if the oral iron is as effective as intravenous iron in increasing the red blood cell count.",[98,28],[98,348,100],"Iron","2025-12-11",{"date":351,"type":41},"2025-12-17",{"date":353,"type":22},"2025-12-31",{"date":141,"type":22},{"name":356,"class":48},"University of Rochester",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":92,"minAge":364,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":49},"100611314","phase-4-postoperative-intravenous-ferric-derisomaltose-for-prevention-of-long-term-anemia-after-cardiac-surgery-100611314","NCT07238972","Postoperative Intravenous Ferric Derisomaltose for Prevention of Long-term Anemia After Cardiac Surgery","Impact of Postoperative Intravenous Iron Supplementation on the Incidence of Long-term Anemia in Patients Undergoing Cardiac Surgery","Inclusion Criteria:\n\n* Adults aged ≥19 years scheduled to undergo cardiac surgery requiring cardiopulmonary bypass Preoperative anemia defined as hemoglobin \\\u003C13.0 g\u002FdL, or preoperative iron deficiency defined as ferritin \\\u003C100 ng\u002FmL or transferrin saturation \\\u003C20% Ability to understand the study information and provide written informed consent prior to surgery\n\nPostoperative day 1 hemoglobin \\\u003C10.0 g\u002FdL on the first CBC following surgery (required for final enrollment)\n\nExclusion Criteria:\n\n* Emergency surgery Preoperative major organ failure requiring intensive care unit management Active infection prior to surgery, including sepsis Active bleeding prior to surgery Pregnancy or breastfeeding Use of erythropoiesis-stimulating agents or intravenous iron therapy within 3 months prior to surgery Iron overload defined as ferritin ≥500 ng\u002FmL or transferrin saturation ≥45% Aplastic anemia Hemolytic anemia Hemochromatosis or hemosiderosis Decompensated liver cirrhosis, acute hepatitis, or alcohol dependence Known hypersensitivity to intravenous iron formulations Participation in another clinical trial that may influence outcomes Inability to understand or provide informed consent due to language barriers, illiteracy, or cognitive impairment","19 Years",{"count":180,"type":22},[156],"Postoperative anemia is highly prevalent among patients undergoing cardiac surgery and is associated with delayed functional recovery, increased morbidity, and impaired long-term outcomes. Preoperative iron deficiency is common in this population and contributes to inadequate erythropoietic recovery after surgery. Functional iron deficiency frequently develops even in patients without preoperative deficiency due to blood loss, hemodilution, and inflammation-mediated disruption of iron homeostasis. Despite this clinical burden, standardized strategies for postoperative anemia management have not been established.\n\nThis prospective, randomized, double-blind, placebo-controlled clinical trial evaluates whether early postoperative intravenous iron supplementation improves long-term anemia outcomes in patients undergoing cardiac surgery with cardiopulmonary bypass. Adult patients with preoperative anemia (hemoglobin \\\u003C13 g\u002FdL) or iron deficiency (ferritin \\\u003C100 ng\u002FmL or transferrin saturation \\\u003C20%) will be screened. Eligible participants with postoperative day (POD) 1 hemoglobin \\\u003C10 g\u002FdL will be randomized in a 1:1 ratio to receive either ferric derisomaltose (20 mg\u002Fkg, maximum 1,000 mg) or a matched placebo administered intravenously over 30 minutes on POD 1. All perioperative management outside the intervention follows current institutional standards.\n\nThe primary outcome is the incidence of anemia at 6 months following surgery. Secondary outcomes include perioperative hemoglobin trends, functional recovery assessed by cardiopulmonary exercise testing and the 6-minute walk test at 6 months, transfusion requirements, postoperative complications including MAKE-90 and STS major morbidity, and changes in biomarkers of erythropoiesis and iron metabolism (erythroferrone, erythropoietin, hepcidin, and iron profile). Blood samples for biomarker analysis are collected at predefined perioperative timepoints.\n\nFerric derisomaltose allows high-dose single-session iron repletion with a favorable safety profile and minimal risk of anaphylaxis when administered slowly. Prior studies in cardiac surgery and heart failure populations support its efficacy and safety at doses up to 20 mg\u002Fkg. The intervention is expected to facilitate erythropoietic recovery, reduce the duration of postoperative anemia, and improve long-term functional status. The trial aims to generate evidence to inform postoperative anemia management strategies in cardiac surgery patients.",[98,369,28,101,370],"Iron Deficiencies","Heart Valve Diseases","2025-11-16",{"date":373,"type":41},"2025-11-20",{"date":375,"type":22},"2025-12",{"date":377,"type":22},"2030-10",{"name":379,"class":48},"Yonsei University",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":92,"minAge":18,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":23,"phases":389,"briefSummary":390,"conditions":391,"keywords":392,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":49},"100383147","phase-3-trial-of-iv-vs-oral-iron-treatment-of-iron-deficiency-anemia-in-the-post-operative-bariatric-surgical-patient-100383147","NCT04268849","Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient","A Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient","Inclusion criteria:\n\n1. Aged ≥ 18 years\n2. Patients who have undergone a Roux-en Y Gastric Bypass or Vertical Sleeve Gastrectomy and are at least 3 months or more out from surgery.\n3. Iron deficiency anemia defined as iron deficient with either ferritin\\\u003C30 mcg\u002Fl, TSAT\\\u003C20%, or anemia with Hgb\\\u003C13 g\u002FdL for both males and females.\n4. Willingness to participate and signing the informed consent form.\n\nExclusion criteria:\n\n1. Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and hemosiderosis)\n2. Decompensated liver cirrhosis or active hepatitis (ALAT \\> 3 times upper limit of normal)\n3. Serum ferritin \\> 400 ng\u002FmL or transferrin saturation \\>40 %\n4. Active acute or chronic infections (assessed by clinical judgment that may be indicated by White Blood Cells (WBC) and C-Reactive Protein (CRP) when these are available)\n5. Rheumatoid arthritis with symptoms or signs of active inflammation\n6. Pregnant and nursing women\n7. History of multiple allergies (two or more)\n8. Known hypersensitivity to ferumoxytol or oral iron or any excipients in the drug products\n9. Previous IV iron treatment for IDA\n10. Other iron treatment or blood transfusion within 4 weeks prior to the screening or treatment visit\n11. Planned elective surgery during the study\n12. Any other medical condition that, in the opinion of Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study, e.g. a malignancy, uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus",{"count":388,"type":22},104,[243],"Given the limited long-term effectiveness of traditional weight loss methods, bariatric surgery is increasingly becoming the preferred option for sustained weight loss. With the ascendancy of the laparoscopic approach, the two most common procedures are the Roux-en-Y gastric bypass (RYGB) and the vertical sleeve gastrectomy (VSG).\n\nBecause bariatric surgery decreases nutrient intake through restriction, malabsorption, or both, and given that obese patients are often malnourished even before surgery, postoperative micronutrient deficiency, particularly of iron, can be a serious complication and difficult to treat. Iron deficiency anemia has been reported to be as high as 49% in the post-bariatric surgical patient.\n\nThe current standard for correcting iron deficiency anemia in the post-operative bariatric surgical patient is oral iron supplements. However, oral iron therapy is known for its caustic effects on the gastric mucosa causing gastric irritation, nausea, epigastric discomfort and constipation. These debilitating symptoms lead to poor adherence and lower long and short-term efficacy. Furthermore, iron absorption from oral iron supplements when taken with food in patients with low iron stores ranges from 2 to 13% and without food 5 to 28%. An alternative and more effective method of iron replenishment is the use of intravenous iron. A litany of published trials, without contradiction, show marked superiority of intravenous iron in improving hemoglobin concentrations and iron parameters when compared to historical controls. Nonetheless, the current recommendations of the American Society of Metabolic and Bariatric Surgery nutritional guidelines, state that oral iron supplementation for IDA is the recommended first line of treatment. Studies are lacking that compare the efficacy of oral versus intravenous (IV) iron therapy for the treatment of IDA in the post-bariatric surgical patient.\n\nThe aim of our study is to compare two accepted treatments for iron deficiency anemia (oral ferrous sulfate and intravenous ferumoxytol) for efficacy and speed of response in the treatment of IDA in the post-operative bariatric surgical patient. In this study, 104 bariatric surgical post-operative patients will be randomly assigned 52 each to oral or 52 to a single dose IV iron treatment using double-blind procedures.\n\nThe primary outcome will be determined at 6 weeks of treatment with a follow-up at 12 months after treatment. Non-responders at 6 weeks after treatment may, if they qualify (based on inclusion\u002Fexclusion criteria), have an open-label IV iron treatment and will be followed with the same evaluations used after the first IV iron treatments.",[28],[280,393,394],"Roux-en-Y gastric bypass (RYGB)","Vertical Sleeve Gastrectomy (VSG)","2025-09-30",{"date":397,"type":41},"2025-10-03",{"date":399,"type":41},"2020-02-27",{"date":401,"type":22},"2026-02",{"name":403,"class":48},"Auerbach Hematology Oncology Associates P C",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":92,"minAge":18,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":416,"conditions":417,"keywords":421,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":49},"100599787","endoscopic-evaluation-for-iron-deficiency-anemia-in-patients-on-antithrombotic-therapy-100599787","NCT07089030","Endoscopic Evaluation for Iron Deficiency Anemia in Patients on Antithrombotic Therapy","A Pilot Study Evaluating the Benefit of Endoscopic Assessment for Iron Deficiency Anemia in Patients Receiving Antithrombotic Therapy","BEACON-IDA","Inclusion Criteria:\n\n1. Adult men and postmenopausal women with iron deficiency anemia, and premenopausal women with iron deficiency anemia and a negative gynecological evaluation;\n\n   a. Laboratory-confirmed iron deficiency anemia (hemoglobin \\\u003C 120 g\u002FL for women, \\\u003C 130 g\u002FL for men, and ferritin \\\u003C 30 ng\u002FL);\n2. Patients receiving anticoagulant or antiplatelet therapy\n3. Negative esophagogastroduodenoscopy (EGD), colonoscopy, and capsule endoscopy for gastrointestinal bleeding within six months prior to study enrollment\n4. Willing and able to provide written informed consent\n5. Able to read and understand French\n\nExclusion Criteria:\n\n1. Ongoing overt gastrointestinal bleeding\n2. Acute coronary syndrome, acute neurological event, sepsis, or respiratory failure within the past week\n3. Pregnant women\n4. Known gastrointestinal or hematological malignancy\n5. Contraindications to capsule endoscopy\n6. History of bariatric surgery, gastrectomy, or segmental resection of the small intestine\n7. Inability to take oral iron\n8. Other sources of blood loss (e.g., urinary, gynecological, hematoma, hemolysis)","90 Years",{"count":414,"type":22},20,[25],"This is a single-center, randomized pilot study evaluating the feasibility and safety of two management strategies for patients on antithrombotic therapy who present with obscure gastrointestinal bleeding (OGIB). Participants will be randomized to either repeated endoscopic evaluations or a conservative medical approach with limited testing. The study aims to assess whether conservative management yields similar clinical outcomes and quality of life compared to standard repeated endoscopic procedures. Results will inform the design of a larger trial and address the current lack of guidelines for managing recurrent iron-deficiency anemia in this patient population.",[418,419,420],"Obscure Gastrointestinal Bleeding","Iron-Deficiency Anemia","Antithrombotic Therapy",[418,419,420,422,423,424,425],"Anticoagulants","Antiplatelet Agents","Endoscopy","Gastrointestinal Hemorrhage","2025-07-25",{"date":428,"type":41},"2025-07-28",{"date":430,"type":41},"2023-06-06",{"date":432,"type":22},"2026-06-06",{"name":434,"class":48},"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":443,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":446,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":459},"100474807","phase-3-intravenous-versus-oral-iron-for-treating-iron-deficiency-anemia-in-pregnancy-100474807","NCT05462704","Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy","Double-blind Placebo-controlled Multicenter Randomized Trial of Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy","IVIDA2","Inclusion Criteria:\n\n* Pregnant women between the ages of 18-45\n* Singleton gestation\n* Iron-deficiency anemia (serum ferritin \\\u003C30ng\u002FmL and Hb\\\u003C11 g\u002FdL)\n* At 13-30 weeks gestation\n* Plan to deliver at participating hospital\n\nExclusion Criteria:\n\n* Non-iron-deficiency anemia e.g thalassemia, sickle cell disease, B12 or folate deficiency, hypersplenism.\n* Malabsorptive syndrome, inflammatory bowel disease, gastric bypass, or sensitivity to oral or IV iron\n* Multiple gestation\n* Inability or unwillingness to provide informed consent\n* Inability to communicate with members of the study team, despite the presence of an interpreter\n* Planned delivery at a non-study affiliated hospital","45 Years",{"count":445,"type":22},300,[243],"Double blind, placebo controlled, multicenter randomized trial in pregnant women in the U.S. (N=300) to test the central hypothesis that IV iron in pregnant women with IDA (Hb\\\u003C11 g\u002FdL and ferritin\\\u003C30 ng\u002FmL) at 13 - 30 weeks will be effective, safe and cost-effective in reducing severe maternal morbidity-as measured by maternal anemia at delivery-and will also improve offspring neurodevelopment.",[28,449],"Pregnancy","2025-06-05",{"date":452,"type":41},"2025-06-10",{"date":454,"type":41},"2023-01-17",{"date":456,"type":22},"2027-03-31",{"name":458,"class":48},"Women and Infants Hospital of Rhode Island",8,{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":57,"sex":17,"minAge":467,"maxAge":18,"enrollmentInfo":468,"targetDuration":4,"studyType":23,"phases":470,"briefSummary":471,"conditions":472,"keywords":473,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":484,"locationsCount":49},"100589692","effect-of-cows-milk-kefir-on-short-chain-fatty-acid-scfa-haemoglobin-and-ferritin-levels-of-anemic-adolescent-girls-100589692","NCT06957717","Effect of Cow's Milk Kefir on Short Chain Fatty Acid (SCFA), Haemoglobin, and Ferritin Levels of Anemic Adolescent Girls","Effect of Cow's Milk Kefir on Short Chain Fatty Acid (SCFA), Haemoglobin, and Ferritin Levels of Anemic Adolescent Girls in Yogyakarta, Indonesia","Inclusion Criteria:\n\n* Adolescent girls aged 15-18 years\n* Have a mild and moderate degree of anemia (Hb 8-11.9 g\u002Fdl)\n* Have a normal menstrual cycle and duration\n\nExclusion Criteria:\n\n* Suffering from thalassemia, hemosiderosis, blood cancer, and malaria, based on the doctor's diagnosis in the last 3 months\n* Taking supplements other than TTD\n* Taking antibiotics in the last 3 months\n* Suffering from lactose intolerance through interviews","15 Years",{"count":469,"type":22},80,[25],"Introduction: The prevalence of anemia among adolescent girls in Indonesia is still quite high. According to the Indonesian Health Survey (IHS) in 2023, it was 18% and is still a national problem. Long-term supplementation of blood supplement tablets (TTD) as an effort made by the government to prevent\u002Fovercome anemia has caused side effects, namely dysbiosis by pathogenic bacteria. Giving cow's milk kefir containing various probiotics can overcome the side effects of supplementation, and its metabolites accelerate iron absorption so that iron status in the blood increases and ultimately restores anemia in adolescent girls. Method: It's research is an experimental study, with a Randomized Controlled Trial (RCT) design, pre-posttest design, involving research subjects of adolescent girls (15-18 years) with mild and moderate anemia, at SMKN 1, 2, and 3 Kasihan, Bantul Regency, Yogyakarta as many as 80 students. Subjects were divided into 2 groups, namely group 1 (treatment group), which was given 120 ml of cow's milk kefir every day and TTD 1 grain\u002Fweek, and group 2 (control group), which was given 120 ml of cow's milk every day and TTD 1 grain\u002Fweek. The duration of administration was 2 months. The study outcomes were Short Chain Fatty Acid (SCFA) levels in feces by Gas Chromatography-Mass Spectrometry (GC-MS) method, hemoglobin by Hematology Analyser method, and serum ferritin by Ferritin ELISA measured at the beginning and end of the study. Statistical analysis included univariate, bivariate, and multivariate analysis. Clinical analysis was also conducted to estimate the effect size of the treatment",[28],[474,475,476,477,28],"Kefir","Short Chain Fatty Acid","Hemoglobin","Ferritin","2025-05-02",{"date":480,"type":41},"2025-05-04",{"date":482,"type":22},"2025-05",{"date":330,"type":22},{"name":485,"class":48},"Lusyana Gloria Doloksaribu",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":92,"minAge":18,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":23,"phases":495,"briefSummary":496,"conditions":497,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":49},"100466408","effect-of-the-combined-programme-on-perioperative-anaemiacppa-100466408","NCT05353348","Effect of the Combined Programme on Perioperative Anaemia（CPPA）","Effectiveness of Iron Sucrose Combined With rHuEPO and Ascorbic Acid in Improving Perioperative Anaemia in Patients Undergoing Major Cardiac Surgery","Inclusion Criteria:\n\n* Age 18 years and above\n* Ferritin \\\u003C300µg\u002FL, transferrin saturation \\\u003C25%, male 90\\\u003CHb\\\u003C130g\u002FL or female 90\\\u003CHb\\\u003C120g\u002FL\n* Elective major cardiac surgery (valve replacement, CABG coronary artery bypass surgery or a combination of both)\n* ASA: Grade 1-3\n* Signed informed consent\n\nExclusion Criteria:\n\n1. Allergy or contraindication to iron sucrose or recombinant human erythropoietin or ascorbic acid\n2. Patients with a preoperative temperature \\>37.5 °C or on non-prophylactic antibiotics\n3. Pregnancy or breastfeeding stage\n4. weight ≤ 50 kg\n5. Presence of chronic renal insufficiency, urinary stones, oxalate deposits, gout\n6. Chronic liver disease and\u002For screening alanine transferase\u002Faspartate transferase above normal 3 times or more above the upper limit of the normal range\n7. Family history of haemochromatosis, thalassaemia or transferrin saturation \\> 50%\n8. Known history of iron overload\n9. Other known causes of anaemia (folic acid or vitamin B12 deficiency or haemoglobinopathies, etc.)\n10. Emergency surgery\n11. Use of iron, blood transfusion or related anaemia treatment within 12 weeks prior to surgery\n\nWithdrawal criteria:\n\n1. massive blood transfusion (≥ 10 red blood cells (RBC)\u002F24h)\n2. Preoperative interventions not performed according to standard\n3. Cancellation of surgery",{"count":494,"type":22},110,[25],"We used the preoperative intervention of iron sucrose in combination with human erythropoietin and vitamin C as an innovative combination therapy. This combined treatment strategy aims to improve perioperative anaemia in patients by promoting erythropoiesis and improving iron metabolism. Compared with previous perioperative intravenous iron supplementation, this innovative combination therapy strategy takes into account multiple aspects of iron metabolism as well as the biological mechanisms of erythropoiesis, providing a more comprehensive intervention. Management of perioperative anaemia in previous studies has largely relied on single intravenous iron supplementation therapy, and although this approach has been effective in raising iron levels, its effectiveness may be limited in patients who have impaired iron utilisation or in situations where concurrent stimulation of erythropoiesis is required. The use of iron sucrose in combination with human erythropoietin and vitamin C, on the other hand, is based on an integrative therapeutic concept aimed at providing a more comprehensive response to perioperative anaemia by simultaneously promoting effective iron utilisation and erythropoiesis.",[498,101,28],"Patient Blood Management","2025-01-08",{"date":501,"type":41},"2025-01-10",{"date":503,"type":41},"2023-03-15",{"date":505,"type":22},"2025-04-01",{"name":110,"class":48},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":57,"sex":92,"minAge":272,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":23,"phases":517,"briefSummary":518,"conditions":519,"keywords":521,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":530,"locationsCount":49},"100573149","comparison-of-efficacy-of-iron-polymaltose-complex-and-ferrous-sulphate-in-iron-deficiency-anemia-in-pediatric-patients-100573149","NCT06742528","Comparison Of Efficacy Of Iron Polymaltose Complex And Ferrous Sulphate In Iron Deficiency Anemia In Pediatric Patients","Comparison Of Efficacy Of Iron Polymaltose Complex And Ferrous Sulphate In Iron Deficiency Anemia In Pediatric Patients With Iron Deficiency Anemia","Inclusion Criteria:\n\n* Patients having iron deficiency anemia\n\nExclusion Criteria:\n\n1. Patients diagnosed as congenital aplastic anemia or thalassemia (Determined from medical record).\n2. Patients who were transfused in previous 4 weeks (will be determined on history)\n3. Children having mal-absorption syndrome and diarrheal illnesses. (will be determined on history and medical record)\n4. Gastrointestinal bleeding suggested by history of hematemesis (bloody vomit), melena (black colored stools) or bloody stools.","5 Years",{"count":516,"type":22},198,[25],"This study aims to compare the efficacy of two iron preparation for the management of children presented with iron deficiency anemia. Ferrous sulphate and lron polymaltose (ferric form) are most commonly used preparations. Both drugs are easily available in market and are often recommended by pediatriclans. The efficacy, bioavail.tbilily, side effects and cost of these preparations vary. This study is designed to find out a drug with better efficacy that can be used for treatment of iron deficiency anemia in local population.",[28,520],"Iron Deficiency, Anaemia in Children",[522,523,520],"IRON POLMALTOSE COMPLEX","FERROUS SULPHATE","2024-12-17",{"date":526,"type":41},"2024-12-19",{"date":528,"type":41},"2024-01-10",{"date":501,"type":22},{"name":531,"class":48},"Arooj Khan",{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":443,"enrollmentInfo":540,"targetDuration":542,"studyType":273,"phases":4,"briefSummary":543,"conditions":544,"keywords":546,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":556,"leadSponsor":557,"locationsCount":4},"100567504","liposomal-iron-30-mg-supplement-in-non-anemic-pregnant-females-100567504","NCT06669052","Liposomal Iron 30 mg Supplement in Non-anemic Pregnant Females","Liposomal Iron 30 mg Supplement in Non-anemic Pregnant Females an Observational Study","LITSNPF","Inclusion Criteria:\n\n* Pregnant females; gestational age from 14 to 16 weeks Age 18-45 years\n* Low-risk pregnancy is defined as a pregnancy in which there is no high risk of problems or unfavorable outcomes, and the expectant mother and fetus are typically healthy\n* Non-anemic women at the time of recruitment (hemoglobin level not less than 10.5. Hemoglobin measured within 2 or 3 weeks of recruitment\n* Singleton pregnancy\n* Agree to participate in the study including data collection from medical records and participation in related questionnaires.\n\nExclusion Criteria:\n\n* Inadequate medical records\n* Pregnant women living in areas away from the recruitment center\n* Had any chronic health problem.\n* Women with any form of hereditary anemia including sickle cell anemia, thalassemia, and Glucose-6-phosphate dehydrogenase (G6PD) deficiency.\n* History of antepartum bleeding\n* Refuse to sign the informed consent.",{"count":541,"type":22},714,"90 Days","Protocol Summary: Liposomal Iron Supplementation in Non-anemic Pregnant Females This observational study aims to evaluate the efficacy and safety of daily liposomal iron supplementation (30 mg) in non-anemic pregnant women during their second trimester of pregnancy. The study will focus on pregnant females aged 18-45 years with low-risk, singleton pregnancies who are non-anemic (hemoglobin ≥10.5) at 14-16 weeks gestation.\n\nPrimary Research Question:\n\nDoes daily supplementation with 30 mg liposomal iron effectively maintain maternal hemoglobin levels over 90 days? Measured by: The difference in maternal hemoglobin levels between baseline and after 90 days of treatment in women recruited at 14-16 weeks gestation.\n\nSecondary Research Questions:\n\nWhat are the effects of liposomal iron supplementation on serum ferritin levels? Measured by: Changes in serum ferritin levels between baseline and after 90 days of treatment.\n\nWhat is the safety profile of liposomal iron supplementation during pregnancy? Measured by: Maternal gastrointestinal side effects monitored at each prenatal visit (day 30, 60, and 90).\n\nWhat is the compliance rate with liposomal iron supplementation? Measured by: Participant-reported compliance assessed at each prenatal visit (day 30, 60, and 90).\n\nParticipants will:\n\nReceive daily liposomal iron supplementation (30 mg) for 90 days. Attend regular prenatal visits for monitoring at days 30, 60, and 90. Complete questionnaires about compliance and any adverse effects at each visit. Undergo blood tests to measure hemoglobin and serum ferritin levels at baseline and day 90.\n\nThis multi-center study will involve 714 participants across 100 sites, with recruitment beginning in November 2024 and study completion expected by July 2025. The study's findings will contribute to understanding the role of liposomal iron supplementation in preventing iron deficiency during pregnancy and its potential advantages over traditional iron supplements in terms of tolerability and compliance.",[545,28],"Anemia of Pregnancy",[547,548,549,550,551],"30 mg liposomal irom","non-anemic pregnant females","observational study","hemoglobin level","Second trimester","2024-10-31",{"date":554,"type":41},"2024-11-01",{"date":554,"type":22},{"date":482,"type":22},{"name":558,"class":260},"Orchidia pharmaceutical Industries",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":247,"eligibilityCriteria":565,"healthyVolunteers":57,"sex":17,"minAge":566,"maxAge":567,"enrollmentInfo":568,"targetDuration":4,"studyType":23,"phases":569,"briefSummary":570,"conditions":571,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":583},"100510691","phase-4-iron-deficiency-anemia-ida-and-the-brain-100510691","NCT05929729","Iron Deficiency Anemia (IDA) and the Brain","Neurovascular and Neurocognitive Consequences of Iron Deficiency Anemia","Inclusion Criteria:\n\n* Observational arm:\n\n  1. Age between 16 and 60 years of age.\n  2. Any ethnicity.\n  3. Female\n  4. Anemic group: hemoglobin ≤10.5 g\u002Fdl or hematocrit \\\u003C32% from finger prick or plethysmography test, or \\\u003C11 g\u002Fdl from venipuncture blood draw\n  5. Control group: hemoglobin \\>13.2 g\u002Fdl or hematocrit \\>39.6%\n* Interventional arm:\n\n  1. Criteria for observational component, plus\n  2. Iron deficiency anemia based upon attending hematologist interpretation of transferrin saturation, ferritin, and other ancillary labs including hs-CRP, MMA, hemoglobin electrophoresis\n\nExclusion Criteria:\n\n* Observational arm:\n\n  1. Diabetes requiring medication.\n  2. Hypertension requiring medication.\n  3. Sleep disordered breathing requiring intervention.\n  4. Body mass index \\>40 (morbid obesity)\n  5. Contraindications to MRI, including pacemaker, severe claustrophobia, pregnancy.\n  6. Known systemic inflammatory disease such as inflammatory bowel disease, systemic lupus erythematosus, or scleroderma.\n  7. Known HIV.\n* Interventional arm:\n\n  1. Criteria for observational component, plus\n  2. Prior reaction to intravenous iron.\n  3. History of multiple drug allergies.\n  4. History of severe asthma, eczema, or atopy.\n  5. Systemic mastocytosis.\n  6. Severe respiratory or cardiac disease.\n  7. Having no access to a physician who can manage the iron deficiency anemia.","16 Years","60 Years",{"count":121,"type":22},[156],"This is a trial with an observational and an interventional arm, in patients with moderate to severe anemia and control subjects. The main purposes of this study is to phenotype the scope of neurocognitive deficits from iron deficiency anemia (IDA) in adult women, determine derangements in cerebral perfusion, vascular reactivity, functional connectivity, and blood brain barrier permeability in adult-onset IDA and relate them to neurocognitive deficits, as well as determine the reversibility and durability of both the physiologic and neurocognitive derangements by iron replacement therapy. All eligible subjects will be asked to provide informed consent before participating in the study.",[572,98,28,573],"IDA - Iron Deficiency Anemia","Anemia, Iron Deficiency","2024-10-28",{"date":576,"type":41},"2024-10-30",{"date":578,"type":41},"2023-12-07",{"date":580,"type":22},"2028-09-01",{"name":582,"class":48},"Children's Hospital Los Angeles",4,{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":92,"minAge":272,"maxAge":591,"enrollmentInfo":592,"targetDuration":4,"studyType":273,"phases":4,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":604,"locationsCount":49},"100566966","impact-of-iron-deficiency-anemia-on-neurobehavioral-and-cognitive-development-in-children-aged-6-to-24-months-100566966","NCT06662045","Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 Months","Study on the Association Between Iron Deficiency Anemia and Neurobehavioral Development and Cognitive Function in Children Aged 6 to 24 Months","Inclusion Criteria:\n\n* Children aged 6 to 24 months at the time of enrollment\n* Diagnosed with iron-deficiency anemia (for the exposure group) or confirmed\n* non-anemic status (for the control group) based on blood test results\n* Resident in the study area for at least 6 months prior to enrollment\n* Availability of parental or guardian consent to participate in the study and willingness to follow study protocols\n* Completion of all baseline assessments, including neurodevelopmental and physical growth evaluations\n\nExclusion Criteria:\n\n* Presence of congenital or chronic illnesses that could affect\n* neurodevelopment, such as Down syndrome or cerebral palsy.\n* History of severe infections or trauma within 3 months prior to enrollment that\n* could influence neurodevelopmental outcomes\n* Current use of medications or treatments that may interfere with iron metabolism (e.g., iron supplementation or blood transfusions in the last 6 months)\n* Premature birth (before 37 weeks of gestation) or low birth weight (\\\u003C 2,500 grams)\n* Parental refusal to provide consent or non-compliance with study procedures.","6 Years",{"count":593,"type":22},1000,"The goal of this observational study is to explore the relationship between iron-deficiency anemia and neurobehavioral development in children aged 6-24 months. This study focuses on children who undergo health check-ups and blood tests at pediatric health clinics in Pingshan District, Shenzhen, China.\n\nThe main questions it aims to answer are:\n\nHow does iron-deficiency anemia affect children's neurobehavioral development, including motor skills, language ability, and social behavior? How does anemia influence growth and nutrition, such as weight, height, and body mass index (BMI) in children?\n\nParticipants will:\n\nUndergo blood tests (including hemoglobin levels, serum ferritin, and serum iron) to assess anemia status.\n\nBe assessed using the \"Neuropsychological Behavioral Development Scale for Children Aged 0-6\" to measure motor, cognitive, language, and social development.\n\nProvide general health information, such as birth history, feeding methods, and parental details, through interviews with trained surveyors.\n\nResearchers will compare children with and without iron-deficiency anemia to determine differences in neurobehavioral outcomes and development levels. The findings aim to provide evidence for early interventions to prevent the negative impacts of anemia and support children's healthy development.",[419,596,597,598],"Neurobehavioral Manifestations","Growth Disorders","Nutritional Status","2024-10-25",{"date":574,"type":41},{"date":602,"type":41},"2024-01-01",{"date":141,"type":22},{"name":605,"class":48},"Pingshan District Maternal & Child Healthcare Hospital of Shenzhen",{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":92,"minAge":58,"maxAge":613,"enrollmentInfo":614,"targetDuration":4,"studyType":23,"phases":616,"briefSummary":617,"conditions":618,"keywords":619,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":4},"100356002","short-term-intravenous-iron-isomaltose-anhydride-for-ida-100356002","NCT03915327","Short-term Intravenous Iron Isomaltose Anhydride for IDA","Short-term Use of Intravenous Iron Isomaltose Anhydride for Preoperative Anemic Patients Undergoing Orthopedic Surgery: a Prospective, Randomized, Controlled Study","Inclusion Criteria:\n\n* Age \\> 14 years;\n* Sign and date the \"informed consent form\"\n\nExclusion Criteria:\n\n* Pregnant or lactation;\n* Drug abuse, including but not limited to opioids, amphetamines, ice, ketamine, etc.;\n* History of anaphylaxis to oral or intravenous iron;\n* Nervous system diseases such as peripheral neuropathy, mental illness;\n* Other conditions that the investigator deems are not suitable for the study, such as deafness, Parkinson's disease, communication disorders, etc.;\n* Participated in other clinical trials during the first three months of the study.","99 Years",{"count":615,"type":22},1600,[25],"This prospective, randomized, controlled study aims to evaluate the impact of short-term intravenous iron isomaltose anhydride on postoperative recovery and the requirement for allogeneic red blood cells (RBC) transfusion in preoperative Iron-deficiency anemia (IDA) patients receiving orthopedic surgery, thus facilitating developing a simple and effective iron supplement approach for patients' recovery.",[28],[620,621,622],"Iron-deficiency anemia","Intravenous iron isomaltose anhydride","Preoperative","2024-05-03",{"date":625,"type":41},"2024-05-06",{"date":627,"type":22},"2024-07-05",{"date":629,"type":22},"2029-05-31",{"name":631,"class":48},"West China Hospital",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":639,"enrollmentInfo":640,"targetDuration":4,"studyType":23,"phases":642,"briefSummary":643,"conditions":644,"keywords":650,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":661,"locationsCount":49},"100503569","impact-of-benazir-nashonuma-program-bnp-on-maternal-and-child-nutritional-status-100503569","NCT05836961","Impact of Benazir Nashonuma Program (BNP) on Maternal and Child Nutritional Status","Evaluating Effectiveness of Benazir Nashonuma Program (BNP) on Maternal and Infant Outcomes: A Non-randomized Intervention Study in Sindh and Punjab","Inclusion Criteria:\n\nIntervention arm: All pregnant women in their first or second trimester, who are enrolled in Benazir Nashonuma Program (BNP).\n\nNon-intervention arm: All pregnant women in their first or second trimester, who are not enrolled in Benazir Nashonuma Program (BNP).\n\nExclusion Criteria:\n\n* Women who intend to migrate or relocate for more than 3 months during the study period will be excluded from the study.\n* Women in the non intervention group who are consuming specialized nutritious food (SNF) from any source at the time of enrollment will be excluded from the study.","49 Years",{"count":641,"type":22},5500,[25],"The purpose of this study is to evaluate the impact of Benazir Nashonuma Program (BNP) which includes specialized nutritious food (SNF) augmented with specific reproductive health interventions during pregnancy on proportion of low birthweight babies and stunting among children, in low income setting of Pakistan. The study aims to answer if:\n\n1. Utilization of Benazir Nashonuma Program (BNP) among pregnant women is effective in reducing the proportion of low birthweight babies, compared to pregnant women who are not utilizing the program, among low income setting population.\n2. Utilization of Benazir Nashonuma Program (BNP) is effective in reducing the proportion of stunting among children, compared to those not utilizing the program, among low income setting population.\n\nParticipants who are enrolled in the Benazir Nashonuma Program (receiving intervention) and those who are not enrolled (not receiving intervention) will be followed throughout pregnancy till delivery. After delivery mother-baby dyad will be followed for a period of 12 months. Compliance of supplementation will be measured, and outcomes (low birthweight and stunting) observed throughout the follow up.",[645,646,647,648,28,649],"Low Birthweight","Stunting","Wasting","Malnutrition, Child","Dietary Habits",[651,652,653,654,646],"Intervention study","Maternal and child nutrition","Benazir Nashonuma Program (BNP)","Low birthweight","2023-04-28",{"date":657,"type":41},"2023-05-01",{"date":659,"type":41},"2023-02-01",{"date":43,"type":22},{"name":662,"class":48},"Aga Khan University",{"id":664,"slug":665,"hasResults":12,"nctId":666,"briefTitle":667,"officialTitle":668,"acronym":669,"eligibilityCriteria":670,"healthyVolunteers":12,"sex":92,"minAge":567,"maxAge":671,"enrollmentInfo":672,"targetDuration":4,"studyType":23,"phases":673,"briefSummary":674,"conditions":675,"keywords":676,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":686,"locationsCount":4},"100493670","phase-4-impact-of-intravenous-iron-on-musculoskeletal-function-in-older-adults-100493670","NCT05708170","Impact of Intravenous Iron on Musculoskeletal Function in Older Adults","Impact of Intravenous Iron (Ferinject) on Musculoskeletal Function Profiles in Older Adults With Iron Deficiency Anaemia (IDA)","FERIDA","Inclusion Criteria:\n\n* Anaemia attributable to iron deficiency\n* Haemoglobin \\\u003C 120 g\u002FL in women, Hb \\\u003C 130 g\u002FL in men\n* Ferritin ≤100 ng\u002FmL or ≤300 ng\u002FmL if transferrin saturation (TSAT) ≤30%\n* Age ≥ 60 to 85 years\n* Ambulatory individuals\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients already taking intravenous or oral iron\n* BMI \\> 40 kg\u002Fm²\n* Uncontrolled hypertension\u002F diabetes\n* Potential medication interactions\n* Hemochromatosis or iron storage disorders\n* Recent treatment with IV antibiotics or red blood cell transfusion\n* Dialysis dependent\n* History of malignancy\n* Pregnant or lactating women\n* Severe hepatic and renal dysfunction\n* Advanced cardiovascular disease and COPD\n* Advanced Neuromuscular disorder\n* Obvious cognitive disability and psychological illness\n* Current treatment with systemic steroids or any other substantive medication\n* Alcohol or any other drug abuse","85 Years",{"count":322,"type":22},[156],"Anaemia is a risk factor for functional decline and frailty in older adults including decreased physical performance and muscle strength, increased hospitalisation risk and mortality, falls, and poorer recovery from activities of daily living. Despite a major gap in human studies, research in animals has demonstrated an interrelationship between iron deficiency anaemia and deteriorated functional capacity and physical performance particularly in older adults. Iron deficiency and associated anaemia is a frequent accompanier of debilitating chronic diseases such as heart failure and chronic lung diseases. These conditions, more commonly seen in older patients, are strongly linked to deterioration in physical function, reduced skeletal muscle mass and quality, frailty, and poor quality of life. Exercise intolerance is also a common feature of these conditions as iron deficiency impairs the capacity of carrying oxygen leading to inability to sustain physical activities. Furthermore, the age-related decline in the muscle mass and quality (so called sarcopenia) and associated frailty has rapidly become a major health concern in the older adults particularly when accompanied by other chronic diseases. Recently, there has been an increasing interest in exploring the role of iron as a causative factor in the development of sarcopenia and related frailty.\n\nIn summary, there is a substantial gap of evidence whether Iron repletion leads to meaningful enhancements in the skeletal muscle function and physical performance in older adults suffering from iron deficiency anaemia. This study will investigate the impact of a standard care intervention (intravenous iron therapy) on muscular function and physical performance in older patients through a range of laboratory assessments.",[28],[677,678,679,680],"Iron Deficiency Anaemia","Skeletal Muscle Function","Musculoskeletal","Ageing","2023-01-23",{"date":659,"type":41},{"date":684,"type":22},"2023-01",{"date":291,"type":22},{"name":687,"class":48},"Liverpool Hope University"]